Novo Nordisk Shareholders Back Turbulent Board Overhaul as Leadership Fractures Deepen and Weight-Loss Pressures Escalate
Novo Nordisk’s shareholders have approved a sweeping board overhaul that reflects deepening fractures at the world’s most influential obesity-drug manufacturer, signalling that the company’s governance crisis is now inseparable from the competitive storm reshaping the weight-loss market. What began as a disagreement over governance norms has quickly merged with far broader anxiety about Novo’s strategic…









